CL2023002322A1 - Derivados de hidroxiheterocicloalquil-carbamoilo - Google Patents

Derivados de hidroxiheterocicloalquil-carbamoilo

Info

Publication number
CL2023002322A1
CL2023002322A1 CL2023002322A CL2023002322A CL2023002322A1 CL 2023002322 A1 CL2023002322 A1 CL 2023002322A1 CL 2023002322 A CL2023002322 A CL 2023002322A CL 2023002322 A CL2023002322 A CL 2023002322A CL 2023002322 A1 CL2023002322 A1 CL 2023002322A1
Authority
CL
Chile
Prior art keywords
hydroxyheterocycloalkyl
carbamoyl derivatives
compounds
formula
carbamoyl
Prior art date
Application number
CL2023002322A
Other languages
English (en)
Spanish (es)
Inventor
Bolli Martin
Gatfield John
Grisostomi Corinna
Remen Lubos
Sager Christoph
Zumbrunn Cornelia
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2023002322A1 publication Critical patent/CL2023002322A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
CL2023002322A 2021-02-09 2023-08-07 Derivados de hidroxiheterocicloalquil-carbamoilo CL2023002322A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2021053084 2021-02-09

Publications (1)

Publication Number Publication Date
CL2023002322A1 true CL2023002322A1 (es) 2024-03-08

Family

ID=80445748

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002322A CL2023002322A1 (es) 2021-02-09 2023-08-07 Derivados de hidroxiheterocicloalquil-carbamoilo

Country Status (13)

Country Link
US (1) US12304902B2 (cg-RX-API-DMAC7.html)
EP (1) EP4291556B1 (cg-RX-API-DMAC7.html)
JP (1) JP7844491B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230145111A (cg-RX-API-DMAC7.html)
CN (1) CN116806219A (cg-RX-API-DMAC7.html)
AU (1) AU2022221092A1 (cg-RX-API-DMAC7.html)
CA (1) CA3207214A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002322A1 (cg-RX-API-DMAC7.html)
ES (1) ES3032987T3 (cg-RX-API-DMAC7.html)
IL (1) IL304923A (cg-RX-API-DMAC7.html)
TW (1) TW202246248A (cg-RX-API-DMAC7.html)
WO (1) WO2022171594A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202308643B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102863667B1 (ko) 2019-08-09 2025-09-23 이도르시아 파마슈티컬스 리미티드 (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh) 2019-08-29 2024-09-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
WO2022073969A1 (en) 2020-10-06 2022-04-14 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
US12291520B2 (en) 2020-11-02 2025-05-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
KR102231732B1 (ko) 2012-10-10 2021-03-23 갈렉틴 테라퓨틱스, 인크. 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물
IN2015DN02573A (cg-RX-API-DMAC7.html) 2012-10-31 2015-09-11 Galecto Biotech Ab
EP2919802A4 (en) 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
CA2970062C (en) 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
ES2734713T3 (es) 2015-07-06 2019-12-11 Gilead Sciences Inc Moduladores Cot y métodos de utilización de los mismos
CN109563119A (zh) 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CA3062649A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof
KR102626669B1 (ko) 2017-05-12 2024-01-17 갈랙틴 사이언시즈, 엘엘씨 질환의 예방 및 치료를 위한 화합물 및 이의 용도
US11267811B2 (en) 2017-09-27 2022-03-08 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
WO2019075045A1 (en) 2017-10-11 2019-04-18 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
JP2021501180A (ja) 2017-10-31 2021-01-14 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーGalectin Sciences, LLC 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用
CN113366007A (zh) 2018-10-15 2021-09-07 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂
CN113286632A (zh) 2018-10-15 2021-08-20 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂前药
US11447517B2 (en) 2018-11-21 2022-09-20 Galecto Biotech Ab Galactoside inhibitor of galectins
US12269819B2 (en) 2019-04-10 2025-04-08 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
JP7674276B2 (ja) 2019-07-03 2025-05-09 ガレクト バイオテック エービー ガレクチンの新規なガラクトシド阻害剤
CA3143078A1 (en) 2019-07-05 2021-01-14 Galecto Biotech Ab Novel galactoside inhibitor of galectins
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
KR102863667B1 (ko) 2019-08-09 2025-09-23 이도르시아 파마슈티컬스 리미티드 (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh) 2019-08-29 2024-09-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
WO2022073969A1 (en) 2020-10-06 2022-04-14 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
US12291520B2 (en) 2020-11-02 2025-05-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives
WO2022184755A1 (en) 2021-03-03 2022-09-09 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives

Also Published As

Publication number Publication date
CN116806219A (zh) 2023-09-26
EP4291556C0 (en) 2025-04-23
EP4291556B1 (en) 2025-04-23
WO2022171594A1 (en) 2022-08-18
KR20230145111A (ko) 2023-10-17
JP7844491B2 (ja) 2026-04-13
CA3207214A1 (en) 2022-08-18
IL304923A (en) 2023-10-01
ZA202308643B (en) 2026-03-25
ES3032987T3 (en) 2025-07-29
AU2022221092A1 (en) 2023-09-21
US20240124427A1 (en) 2024-04-18
TW202246248A (zh) 2022-12-01
JP2024506182A (ja) 2024-02-09
US12304902B2 (en) 2025-05-20
EP4291556A1 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
CL2022003646A1 (es) Derivados de amidopirimidona
ES3032987T3 (en) Hydroxyheterocycloalkane-carbamoyl derivatives
UY39296A (es) Azaquinolonas sustituidas inhibidoras de parp y composiciones farmacéuticas que las contienen
CL2023002578A1 (es) Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos
CL2019003281A1 (es) Derivados de piperidina. (divisional solicitud 201900169)
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
UY31069A1 (es) Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
CO6531445A2 (es) Derivados bencimidazol-imidazol
MX2023005039A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo que inhiben la galectina-3.
BR122019010008B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
PY2201650A (es) Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos
UY31071A1 (es) Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones
MX2019013639A (es) Derivados de indol n-sustituidos.
PY2039849A (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
CL2020001817A1 (es) Moduladores del receptor c5a
UY38998A (es) Derivados de bencimidazol, su uso en medicina y composiciones que los contienen
CL2021003348A1 (es) Derivados de piridin–3–ilo.
ECSP24007534A (es) Inhibidores de transglutaminasas
ECSP21024078A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
CO2023010155A2 (es) Derivados de pirazolamida
CL2023001138A1 (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo inhibidores de galectina-3